Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal
injection of BIIB111 in participants with Choroideremia (CHM) who have been previously
treated with BIIB111 and who have exited an antecedent study; these treated participants will
be compared with untreated control participants who have exited the STAR (NCT03496012) study
and BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been
previously treated with BIIB112 and who have exited an antecedent study.
Phase
Phase 3
Funding Agency/Sponsor
Other
Disease
Other
Enrollment Eligibility
Key Inclusion Criteria:
CHM Participants
a. Have participated in and exited from an interventional study that investigated the
safety and efficacy of a sub-retinal injection of BIIB111 for CHM.
XLRP Participants
a. Have received a sub-retinal injection of BIIB112 for XLRP and have exited an antecedent
study.
Key Exclusion Criteria:
Participants are not eligible for study participation if they meet the following exclusion
criterion.
a. In the opinion of the Investigator and/or the Sponsor, it is not in the participant's
best interest to participate in the study.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.